Celestone Soluspan Shortage: What Providers and Prescribers Need to Know in 2026

Celestone Soluspan (betamethasone sodium phosphate and betamethasone acetate injectable suspension, 6 mg/mL) has long been a cornerstone corticosteroid in orthopedics, rheumatology, sports medicine, and allergy/immunology. Its dual-component formulation — providing both rapid onset (via the soluble sodium phosphate fraction) and sustained release (via the acetate fraction) — makes it uniquely versatile. But supply disruptions continue to affect practices in 2026. This briefing provides prescribers with a current clinical assessment, substitution guidance, and tools for managing affected patients.

Current Supply Landscape

Celestone Soluspan is manufactured by Organon and available in a 5 mL multi-dose vial (6 mg/mL; NDC: 0052-0432-01). The FDA-approved generic (betamethasone sodium phosphate and betamethasone acetate injection, 6 mg/mL) is produced by manufacturers including American Regent. Despite two available supply streams, medical distributors have flagged active Drug Shortage Alert Warnings for this product in 2026.

Root causes of recurring shortages include:

• Limited manufacturing sites capable of producing the dual-salt betamethasone suspension
• Demand substitution from Depo-Medrol (methylprednisolone acetate) shortages — providers switching to betamethasone deplete its supply
• Thin profit margins on generic injectables reducing investment in redundant production capacity
• Historical supply chain vulnerabilities dating to early-2000s FDA consent decree involving original manufacturer Schering-Plough

Clinical Profile Reminder: Why Celestone Soluspan Is Difficult to Fully Substitute

Celestone Soluspan's unique value lies in its dual pharmacokinetic profile:

• Betamethasone sodium phosphate (3 mg/mL): Highly water-soluble; rapidly absorbed; provides fast onset anti-inflammatory and analgesic effect within hours.
• Betamethasone acetate (3 mg/mL): Slightly soluble depot preparation; slowly absorbed from injection site; provides sustained anti-inflammatory activity lasting days to weeks.

No single alternative corticosteroid replicates this biphasic profile. Substitutes provide either rapid or sustained action, but not both simultaneously from a single injection.

Substitution Options by Clinical Scenario

Intra-articular and Soft Tissue Injections

Triamcinolone acetonide (Kenalog or generic) is the most direct substitute. Provide 10–40 mg intra-articularly depending on joint size, consistent with established protocols. Methylprednisolone acetate (Depo-Medrol, 20–80 mg) is also suitable if available, noting it too faces intermittent supply constraints in 2026.

Intramuscular (IM) Systemic Use

For systemic IM administration (e.g., severe allergic conditions, acute MS exacerbations), dexamethasone sodium phosphate provides reliable rapid action. For situations requiring sustained IM depot effect, triamcinolone acetonide IM or methylprednisolone acetate IM are reasonable alternatives with dose conversion as follows:

• Betamethasone 0.6 mg ≈ Methylprednisolone 4 mg ≈ Dexamethasone 0.75 mg ≈ Prednisone 5 mg ≈ Triamcinolone 4 mg (approximate equivalencies for systemic anti-inflammatory effect only)

Intralesional Use (Dermatology)

Triamcinolone acetonide injection (2.5–10 mg/mL concentration depending on lesion type) is the primary alternative for intralesional use in conditions such as keloids, alopecia areata, and psoriatic plaques. Dilution with normal saline or lidocaine is typical for intralesional protocols.

Sourcing Strategies for Practices

If your primary distributor is out of stock, consider the following:

1. Contact multiple distributors. AmerisourceBergen, McKesson, Cardinal Health, and smaller regional distributors may have differing availability.
2. Request both brand and generic. Ask distributors specifically for 'betamethasone sodium phosphate and betamethasone acetate injection, 6 mg/mL' (generic) in addition to Celestone Soluspan brand.
3. Contact Organon directly. Organon's customer service may be able to identify alternative ordering channels or direct you to distributors with available inventory.
4. Monitor the FDA Drug Shortage Database. Check ashp.org/drug-shortages or the FDA's Drug Shortage Database regularly for official shortage designations and recommended alternatives.

Helping Patients Find Their Medication

For patients who need to fill a Celestone Soluspan prescription at a retail or specialty pharmacy, medfinder for Providers allows you to send patients to a service that calls pharmacies in their area to find which ones have the medication in stock. Results are texted to the patient, eliminating the time burden on both your staff and the patient.

Summary Recommendations

• Maintain a standing substitution protocol: triamcinolone acetonide (Kenalog/generic) for intra-articular use; dexamethasone for rapid IM effect.
• Source both brand (Celestone Soluspan) and generic (betamethasone sod phos/acetate) from multiple distributors.
• Communicate proactively with patients about potential delays and available alternatives.
• Use medfinder to help patients locate their prescription when it needs to be filled externally. Learn more at medfinder.com/blog/how-to-help-your-patients-find-celestone-soluspan-in-stock-provider-guide.